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Abstract
Background: Left atrial thrombi have traditionally been treated with heparin and warfarin, and many physicians
have limited experience with direct oral anticoagulants such as apixaban. Furthermore, the efficacy of apixaban for
the treatment of left atrial thrombi has not been established. We experienced a case of left atrial thrombus
formation before breast cancer surgery, which was resolved by apixaban.
Case presentation: Computed tomography for a 74-year-old Japanese woman with breast cancer incidentally
revealed a left atrial mass with a root before the breast surgery. The mass was surgically removed and determined to
be a thrombus. Before the breast surgery, transthoracic echocardiography was performed again, and the left atrial
thrombus had recurred within only 14 days. It resolved after administration of apixaban.
Conclusions: A left atrial thrombus might recur within a very short time. Apixaban might be an alternative to
warfarin in patients with breast cancer and left atrial thrombus.
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Background
Left atrial thrombus is one of the differential diagnoses
of a left atrial mass and is usually observed in the left
atrial appendage. Historically, left atrial thrombi have
been treated with heparin and warfarin. Recently, direct
oral anticoagulants (DOACs) have been developed, and
the superiority of DOACs to warfarin in preventing
stroke and reducing bleeding has been demonstrated
[1]. However, the efficacy of a DOAC such as apixaban
for the treatment of left atrial thrombus has not been
established. We experienced a case of a left atrial mass
in a patient with breast cancer. The mass was a thrombus
that recurred in only 14 days and then resolved com-
pletely after approximately 2 months of apixaban
administration.
Case presentation
A 74-year-old Japanese woman (height 136 cm; weight
40 kg) without systemic disease presented to our hos-
pital with a palpable 15-mm mass in her left breast that
was identified as stage I breast cancer. Before surgery for
removal of the mass, a contrast-enhanced pulmonary
computed tomography (CT) was performed and showed
a mass approximately 30 × 30 mm in her left atrium
(Fig. 1).
Based on transthoracic echocardiography (TTE), her
left ventricle ejection fraction was 65.3 % and her left
atrial diameter was 42 mm; the mass was 33 × 30 mm, it
had a root, it was located on the surface of the septal
wall, and was oscillating (Fig. 2). An electrocardiogram
showed paroxysmal atrial fibrillation. Her chest radi-
ography was normal. Her CHA2DS2-VASc score was
2, CHADS2 score was 0, and HAS-BLED score was 1.
Laboratory investigations revealed the following:
hemoglobin level, 12.8 g/dL; serum creatinine level,
0.67 mg/dL; estimated glomerular filtration rate,
64.6 mL/minute/1.73 m2; brain natriuretic peptide,
199.2 pg/dL; international normalized ratio (INR),
1.04; activated partial thromboplastin time (APTT),
32.5 seconds; protein C, 113 %; protein S, 75 %; antinu-
clear antigen, 40; and lupus anticoagulant, 1.4 seconds.
Her levels of cancer antigen 15-3 and NCC-ST 439 were
23.8 U/mL and 1.3 U/mL, respectively.
Cardiac surgery was performed 16 days after her first
visit to remove the left atrial mass. On pathologic
examination, the mass consisted of a thrombus, without
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tumor cells (Fig. 3). After removal of the left atrial
mass, heparin was initiated, and breast surgery was
planned.
Fourteen days after her cardiac surgery, TTE was per-
formed, showing a mass formation in the lateral wall of
her left atrium (Fig. 4). The mass was 38 × 31 mm and
was potentially a thrombus. Therefore, her breast oper-
ation was postponed and 1 mg/day of letrozole was
administered to prevent progression of the breast cancer.
The left atrial thrombus was treated with heparin and
warfarin. Because her INR level fluctuated, rivaroxaban
was administered. However, owing to gastrointestinal
upset, she did not take rivaroxaban; therefore, 5 mg of
apixaban twice a day was prescribed. Approximately
2 months later, TTE and contrast-enhanced pulmonary
Fig. 2 Transthoracic echocardiography showing a 33 × 30-mm mass
in the left atrium (white arrow)
Fig. 3 Left atrial mass pathology showing the mass was composed of a thrombus, without tumor tissue
Fig. 1 A 30 × 30-mm mass in the left atrium on contrast-enhanced
computed tomography of the chest (black arrow)
Fig. 4 Fourteen days after cardiac surgery, a thrombus had formed
over the lateral left atrium wall (white arrow)
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CT showed resolution of the left atrial thrombus (Fig. 5).
After complete resolution of the left atrial thrombus, her
breast surgery was performed. During the anticoagula-
tion therapy, thromboembolism and lethal hemorrhage
did not occur.
Discussion
This case highlighted three important clinical issues.
First, apixaban effectively resolved the left atrial
thrombus. DOACs such as apixaban have recently been
developed and are superior to warfarin for preventing
stroke and reducing bleeding [1]. Although there have
been some case reports of resolution of a left atrial
thrombus with apixaban [2–4], the mechanisms of
thrombus resolution are not fully understood. One pos-
sible mechanism is that antithrombin is not required
for the antithrombotic activity of apixaban, which is a
selective factor Xa inhibitor. It inhibits both free and
clot-bound factor Xa as well as prothrombinase activity.
It indirectly inhibits platelet aggregation and decreases
thrombin generation and fibrin clot development [5, 6].
In addition, the fibrinolytic system plays a role in
thrombus resolution. Because of the limited experience
with DOACs for left atrial thrombus resolution, add-
itional cases and further investigation are needed to es-
tablish the efficacy of apixaban for this purpose.
Second, the cardiac thrombus relapsed in a very short
time after removal. Our patient had paroxysmal atrial
fibrillation and cancer. Malignancy has a significant
role in a thrombus, and venous and arterial thrombo-
embolisms are common complications for patients with
cancer [7]. In a normal coagulation-fibrinolysis system,
there is a natural balance between activation and inhib-
ition of procoagulants and anticoagulants. Cancer cells
can alter this balance through the production of
cancer-related procoagulants such as tissue factor and
cancer procoagulant [8]. Tissue factor is a transmem-
brane glycoprotein and the primer of the physiological
coagulation cascade. Cancer procoagulant, a cysteine
protease, is a direct activator of factor X and is found
in malignant tissues. Cancer procoagulant, in the presence
of factor V, enhances thrombin production [9]. Tumor-
specific activation of factor X might be an important step
in the blood coagulation cascade in patients with cancer.
In our case, we used a direct Xa inhibitor (apixaban),
which resulted in a favorable outcome.
Finally, differential diagnoses of intracardiac mass are
a benign tumor, malignant tumor, metastatic tumor, and
thrombus. Atrial myxoma is the most common primary
intracardiac tumor in adults; two thirds of myxomas
arise in the left atrium [10]. However, cardiac thrombi
typically occur in the left atrial appendage. In the
present case, the left atrial mass had a root and oscil-
lated, which are typical characteristics of myxomas and
atypical characteristics of a left atrial thrombus.
Conclusion
Apixaban is a favorable alternative therapy for patients
with a cardiac thrombus.
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